Cantor Fitzgerald Brokers Boost Earnings Estimates for SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Soleno Therapeutics in a research report issued to clients and investors on Wednesday, July 16th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($2.10) per share for the year, up from their prior estimate of ($3.44). Cantor Fitzgerald has a “Overweight” rating and a $123.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Cantor Fitzgerald also issued estimates for Soleno Therapeutics’ FY2026 earnings at $0.84 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.19.

Several other equities research analysts have also recently issued reports on SLNO. Guggenheim lifted their price objective on Soleno Therapeutics from $81.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. UBS Group set a $105.00 target price on Soleno Therapeutics in a report on Thursday, March 27th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Soleno Therapeutics in a report on Tuesday, April 15th. Stifel Nicolaus boosted their target price on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, March 28th. Finally, Cowen assumed coverage on Soleno Therapeutics in a report on Monday, June 23rd. They set a “buy” rating on the stock. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $108.70.

Soleno Therapeutics Trading Down 0.5%

SLNO stock opened at $87.20 on Friday. The company has a current ratio of 19.64, a quick ratio of 19.64 and a debt-to-equity ratio of 0.21. Soleno Therapeutics has a 12-month low of $41.50 and a 12-month high of $90.32. The stock has a market cap of $4.39 billion, a price-to-earnings ratio of -18.87 and a beta of -2.63. The business’s 50-day moving average is $79.81 and its 200 day moving average is $64.04.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after acquiring an additional 189 shares during the last quarter. Moody Aldrich Partners LLC raised its position in Soleno Therapeutics by 0.7% in the first quarter. Moody Aldrich Partners LLC now owns 29,810 shares of the company’s stock valued at $2,130,000 after purchasing an additional 196 shares during the period. Avanza Fonder AB raised its position in Soleno Therapeutics by 14.8% in the first quarter. Avanza Fonder AB now owns 1,951 shares of the company’s stock valued at $144,000 after purchasing an additional 251 shares during the period. AlphaQuest LLC raised its position in Soleno Therapeutics by 37.5% in the first quarter. AlphaQuest LLC now owns 983 shares of the company’s stock valued at $70,000 after purchasing an additional 268 shares during the period. Finally, SG Americas Securities LLC raised its position in Soleno Therapeutics by 8.6% in the first quarter. SG Americas Securities LLC now owns 4,397 shares of the company’s stock valued at $314,000 after purchasing an additional 350 shares during the period. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Patricia C. Hirano sold 3,830 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total value of $316,970.80. Following the transaction, the insider directly owned 13,206 shares in the company, valued at approximately $1,092,928.56. This represents a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 6.40% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.